NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment of Colleen Sjogren as Chief Commercial Officer. Ms. Sjogren will lead the Company’s commercial strategy and operations, including marketing, sales, and market access.
“We are thrilled to welcome Colleen as Nuvation Bio’s first Chief Commercial Officer. She is an accomplished leader who has developed innovative, high-performing commercial organizations for successful product launches, including many leading oncology medicines. Of note, Colleen was one of my commercial superstars at Medivation when we launched XTANDI®,” said David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio. “Colleen joins us at an exciting moment, as we work toward transforming into a late-stage global oncology company with the potential to become commercial-stage by the end of 2025, all while advancing multiple novel therapies for patients with the most difficult-to-treat cancers.”
“I am excited to join Nuvation Bio at this critical point in the company’s transformation to a commercial-stage organization. I look forward to reuniting with David after our successful time together at Medivation and continuing our shared goal of improving the lives of people with cancer,” said Ms. Sjogren. “I have dedicated my career to designing effective commercial organizations for innovative and disruptive new therapies, and I look forward to working with the talented team at Nuvation Bio to build out the company’s commercial strategies and capabilities.”
Ms. Sjogren most recently served as the Senior Vice President of U.S. Sales at Madrigal Pharmaceuticals, where she developed the commercial sales launch plan for a first-in-class, first-to-market therapy. Previously, she was the Vice President of U.S. Sales, Sales Training, and Meeting Planning at Mirati Therapeutics, where she led the build-out of the field-facing commercial organization for the company’s first targeted oncology product launch. Prior to that role, Ms. Sjogren was the Vice President of the National Cell Therapy Team/Sales and Commercial Operations at Kite Pharma, a Gilead company, and held senior leadership roles at Medivation, Human Genome Sciences, Genentech, and Centocor. She received her B.S. and B.A. from Bryant University.
About Nuvation Bio
Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio’s proprietary portfolio includes mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world’s leading prostate cancer medicines. Nuvation Bio has offices in New York and San Francisco. For more information, please visit www.nuvationbio.com and https://www.linkedin.com/company/nuvationbio/.
Forward Looking Statements
Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, the expected closing of the acquisition of AnHeart Therapeutics, the expected timing of establishing a commercial organization and the potential therapeutic benefit of Nuvation Bio’s product candidates. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the management team of Nuvation Bio and are not predictions of actual performance. These forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ from those anticipated by the forward-looking statements, including but not limited to the risk that the acquisition of AnHeart Therapeutics may not close due to the failure of closing conditions to be satisfied or other reasons and the challenges associated with conducting drug discovery and initiating or conducting clinical trials due to, among other things, difficulties or delays in the regulatory process, enrolling subjects or manufacturing or acquiring necessary products; the emergence or worsening of adverse events or other undesirable side effects; risks associated with preliminary and interim data, which may not be representative of more mature data; and competitive developments. Risks and uncertainties facing Nuvation Bio are described more fully in its Form 10-K filed with the SEC on February 29, 2024, under the heading “Risk Factors,” and other documents that Nuvation Bio has filed or will file with the SEC. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this press release. Nuvation Bio disclaims any obligation or undertaking to update, supplement or revise any forward-looking statements contained in this press release.
